Treatment of chronic myeloid leukemia with imatinib mesylate (Q36540561)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2006

edit

Language	Label	Description	Also known as
English	Treatment of chronic myeloid leukemia with imatinib mesylate	scientific article published on June 2006

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Treatment of chronic myeloid leukemia with imatinib mesylate (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

main subject

chronic myeloid leukemia

0 references

imatinib

1 reference

based on heuristic

inferred from title

author name string

Ryuzo Ohno

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

publication date

1 June 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

published in

International Journal of Clinical Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

volume

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

page(s)

176-183

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

cites work

Loss of response to imatinib: mechanisms and management

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular biology of chronic myeloid leukemia.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myelogenous leukemia: a review and update of therapeutic strategies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of early stage disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia: a model for oncology

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Residual Disease in Chronic Myeloid Leukemia after Induction of Molecular Remission

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current trends in hematopoietic stem cell transplantation in Europe

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history and staging of chronic myelogenous leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/16850123

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10147-006-0582-5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

PubMed publication ID

16850123

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16850123

retrieved

14 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36540561&oldid=2199013202"